COVID-19 and cardiovascular diseases: a dangerous tandem
- Authors: Avdeeva I.V.1, Burko N.V.1, Makarova K.N.1, Makarova K.N.1, Oleynikov V.E.1
-
Affiliations:
- Penza State University
- Issue: Vol 7, No 5 (2021)
- Pages: 96-102
- Section: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/288325
- DOI: https://doi.org/10.18565/therapy.2021.5.96-102
- ID: 288325
Cite item
Abstract
Full Text
About the authors
Irina V. Avdeeva
Penza State University
Email: eliseeva.iv1@gmail.com
PhD, associate professor of the Department of therapy of the Faculty of general medicine
Nadezhda V. Burko
Penza State University
Email: hopeful.n@mail.ru
PhD, associate professor of the Department of therapy of the Faculty of general medicine
Karina N. Makarova
Penza State University
Email: makarovakarishka7@rambler.ru
postgraduate student of the Department of therapy of the Faculty of general medicine
Kristina N. Makarova
Penza State University
Email: hristinamack4rova@yandex.ru
postgraduate student of the Department of therapy of the Faculty of general medicine
Valentin E. Oleynikov
Penza State University
Email: v.oleynikof@gmail.com
MD, professor, head of the Department of therapy of the Faculty of general medicine
References
- Driggin E., Madhavan M.V., Bikdeli B. et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J. Am Coll Cardiol. 2020; 75(18): 2352-71. doi: 10.1016/j.jacc.2020.03.031.
- Hendren N.S., Drazner M.H., Bozkurt B. et al. Description and proposed management of the acute COVID19 cardiovascular syndrome. Circulation. 2020; 141(23): 1903-14. doi.org/10.1161/CIRCULATIONAHA.120.047349.
- Hendren N.S., Grodin J.L., Drazner M.H. Unique patterns of cardiovascular involvement in COVID-19. J. Card Fail. 2020; 26(6): 466-69. doi: 10.1016/j.cardfail.2020.05.006.
- ESC European Society of Cardiology. ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic. Available at: https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID19-Guidance (date of access - 22.04.2021).
- Шляхто Е.В., Конради А.О., Арутюнов Г.П. с соавт. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19. Российский кардиологический журнал. 2020; 3: 1-20. doi: https://dx.doi.org/10.15829/1560-4071-2020-3-3801.
- Jaffe A.S., Cleland J.G.F., Katus H.A. Myocardial injury in severe COVID-19 infection. Eur. Heart J. 2020; 41 (22): 2080-82. doi: 10.1093/ eurheartj/ehaa447.
- Babapoor-Farrokhran S., Gill D., Walker J. et al. Myocardial injury and COVID-19: Possible mechanisms. Life Sci. 2020; 253: 117723. doi: 10.1016/j.lfs.2020.117723.
- Zhang H., Penninger J.M., Li Y. et al. Angiotensinconverting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020; 46(4): 586-90. doi: 10.1007/s00134-020-05985-9.
- Guo T., Fan Y., Chen M. et al. Cardiovascular Implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(7): 811-18. doi: 10.1001/jamacardio.2020.1017.
- Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5.
- Preeti M., Urvish P., Nidhi H.P. et al. Elevated cardiac troponin I. as a predictor of outcomes in COVID-19 hospitalizations: a metaanalysis. Infez Med. 2020; 28(4): 500-06.
- Sardu C., Gambardella J., Morelli M.B. et al. Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J. Clin Med. 2020; 9(5): 1417. doi: 10.3390/jcm9051417.
- Guzik T., Mohiddin S.A., Dimarco A. et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc. Res. 2020; 116(10): 1666-87. doi: 10.1093/cvr/cvaa106.
- Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061-69. doi: 10.1001/jama.2020.1585.
- Барбараш О.Л., Каретникова В.Н., Кашталап В.В. с соавт. Новая коронавирусная болезнь (COVID-19) и сердечно-сосудистые заболевания. Комплексные проблемы сердечно-сосудистых заболеваний. 2020; 2: 17-28. doi: https://dx.doi.org/10.17802/2306-1278-2020-9-2-17-28.
- Desai A.D., Boursiquot B.C., Melki L. et al. Management of arrhythmias associated with COVID-19. Curr Cardiol Rep. 2020; 23(1): 2. doi: 10.1007/s11886-020-01434-7.
- Onder G., Rezza G., Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020; 323(18): 1775-76. doi: 10.1001/jama.2020.4683.
- Berman J.P., Abrams M.P., Kushnir A. et al. Cardiac electrophysiology consultative experience at the epicenter of the COVID-19 pandemic in the United States. Indian Pacing Electrophysiol J. 2020; 20(6): 250-56. doi: 10.1016/j.ipej.2020.08.006.
- Ambrus D.B., Benjamin E.J., Bajwa E.K. et al. Risk factors and outcomes associated with new-onset atrial fibrillation during acute respiratory distress syndrome. J. Crit Care. 2015; 30(5): 994-97. doi: 10.1016/j.jcrc.2015.06.003.
- Kochi A.N., Tagliari A.P., Forleo G.B. et al. Cardiac and arrhythmic complications in patients with COVID-19. J. Cardiovasc Electrophysiol. 2020; 31(5): 1003-08. doi: 10.1111/jce.14479.
- Yang C., Jin Z. An acute respiratory infection runs into the most common noncommunicable epidemic - COVID-19 and cardiovascular diseases. JAMA Cardiol. 2020; 5(7): 743-44. doi: 10.1001/jamacardio.2020.0934.
- Holt A., Gislason G.H., Schou M. et al. New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people. Eur Heart J. 2020; 41(32): 3072-79. doi: 10.1093/eurheartj/ehaa494.
- Baldi E., Sechi G.M., Mare C. et al. Out-of-hospital cardiac arrest during the Covid-19 outbreak in Italy. N. Engl J. Med. 2020; 383(5): 496-98. doi: 10.1056/NEJMc2010418.
- Baldi E., Sechi G.M., Mare C. et al. COVID-19 kills at home: the close relationship between the epidemic and the increase of out-ofhospital cardiac arrests. Eur Heart J. 2020; 41(32): 3045-54. doi: 10.1093/eurheartj/ehaa508.
- Schwartz P.J., Crotti L., Insolia R. Long-QT syndrome. From genetics to management. Circ Arrhythm Electrophysiol. 2012; 5(4): 868-77. doi: 10.1161/CIRCEP.111.962019.
- Бубнова М.Г., Аронов Д.М. COVID-19 и сердечно-сосудистые заболевания: от эпидемиологии до реабилитации. Пульмонология. 2020; 5: 688-699. doi: https://dx.doi.org/10.18093/0869-0189-2020-30-5-688-699.
- Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020; 81(5): 537-40. doi: 10.1002/ ddr.21656.
- Li M.Y., Li L., Zhang Y. et al. Expression of the SARSCoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. 2020; 9(1): 45. doi: 10.1186/s40249-020-00662-x.
- Li B., Yang J., Zhao F. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020; 109(5): 531-38. doi: 10.1007/s00392-020-01626-9.
- Shi S., Qin M., Cai Y. et al. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020; 41 (22): 2070-2079. doi: 10.1093/eurheartj/ehaa408.
- Kreutz R., Algharably E.A., Azizi M. et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: Implications for COVID-19. Cardiovasc Res. 2020; 116(10): 1688-99. doi: 10.1093/cvr/cvaa097.
- Драпкина О.М., Палаткина Л.О., Зятенкова Е.В. Плейотропные эффекты статинов. Влияние на жесткость сосудов. Врач. 2012; 9: 5-9.
- Яковенко Е.И., Мамедов М.Н. Влияние метаболических эффектов статинов на клинические проявления атеросклероза. Российский кардиологический журнал. 2012; 2: 85-90. doi: https://dx.doi.org/10.15829/1560-4071-2012-2-85-90.
- Grifoni E., Valoriani A., Cei F. et al. Interleukin-6 as prognosticator in patients with COVID-19. J. Infect. 2020; 81(3): 452-82. doi: 10.1016/j.jinf.2020.06.008.
- Loppnow H., Zhang L., Buerke M. et al. Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. J. Cell Mol Med. 2011; 15(4): 994-1004. doi: 10.1111/j.1582-4934.2010.01036.x.
- Chow R., Im J., Chiu N. et al. The protective association between statins use and adverse outcomes among COVID-19 patients: a systematic review and meta-analysis. British Medical Journal Yele. Available at: https://www.medrxiv.org/content/10.1101/2020.12.18.20248317v1.full-text (date of access - 22.04.2021). doi: 10.1101/2021.02.08.21251070.
- Reiner Z., Hatamipour M., Banach M. et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci. 2020; 16(3): 490-96. doi: 10.5114/aoms.2020.94655.
- Daniels L.B., Sitapati A.M., Zhang J. et al. Relation of statin use prior to admission to severity and recovery among COVID-19 inpatients. Am J. Cardiol. 2020; 136: 149-55. doi: 10.1016/j.amjcard.2020.09.012.
- Hariyanto T.I., Kurniawan A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr. 2020; 14(6): 1613-15. doi: 10.1016/j.dsx.2020.08.023